Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
Sikander Ailawadhi(Jacksonville College), Yifan Zhai(Unknown), Asher Chanan‐Khan(WinnMed), Hengbang Wang, Aneel Paulus(WinnMed), Zi Chen(Central South University), Zhicong He(Pharmaxis (Australia)), Mary C. Collins(Dana-Farber Cancer Institute), Divya J. Mekala(Vifor Pharma (United States)), Ricardo Parrondo(Jacksonville College), Lei Fu(Vifor Pharma (United States)), Laura Glass(Vifor Pharma (United States)), Matthew S. Davids(Dana-Farber Cancer Institute), Costas K. Yannakou(Epworth Hospital), Bo Huang(Suzhou Thermal Engineering Research Institute), Lichuang Men(Suzhou Thermal Engineering Research Institute), Mohammad Ahmad(Vifor Pharma (United States)), Masa Lasica(St Vincent's Hospital Melbourne), Mingyu Li(Vifor Pharma (United States)), Dajun Yang(Ascendis Pharma (Denmark)), Eric Liang(Vifor Pharma (United States))
Cited by 38
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695